DOCSLIB.ORG

1 SB333 2 158141-2 3 by Senator Orr 4 RFD: Judiciary 5 First Read: 11-FEB-14

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 SB333 2 158141-2 3 by Senator Orr 4 RFD: Judiciary 5 First Read: 11-FEB-14 1 SB333 2 158141-2 3 By Senator Orr 4 RFD: Judiciary 5 First Read: 11-FEB-14 Page 0 SB333 1 SB333 2 3 4 ENROLLED, An Act, 5 Relating to Schedule I controlled substances; to 6 amend Sections 13A-12-231 and 20-2-23, Code of Alabama 1975, 7 to increase the requisite weight for trafficking in controlled 8 substance analogues; to include additional synthetic 9 controlled substances and analogues to the Schedule I 10 controlled substances list; and in connection therewith would 11 have as its purpose or effect the requirement of a new or 12 increased expenditure of local funds within the meaning of 13 Amendment 621 of the Constitution of Alabama of 1901, now 14 appearing as Section 111.05 of the Official Recompilation of 15 the Constitution of Alabama of 1901, as amended. 16 BE IT ENACTED BY THE LEGISLATURE OF ALABAMA: 17 Section 1. This act shall be known and may be cited 18 as Landon's Law. 19 Section 2. Sections 13A-12-231 and 20-2-23, Code of 20 Alabama 1975, are amended to read as follows: 21 "§13A-12-231. 22 "Except as authorized in Chapter 2, Title 20: 23 "(1) Any person who knowingly sells, manufactures, 24 delivers, or brings into this state, or who is knowingly in 25 actual or constructive possession of, in excess of one kilo or Page 1 SB333 1 2.2 pounds of any part of the plant of the genus Cannabis, 2 whether growing or not, the seeds thereof, the resin extracted 3 from any part of the plant, and every compound, manufacture, 4 salt, derivative, mixture, or preparation of the plant, its 5 seeds, or resin including the completely defoliated mature 6 stalks of the plant, fiber produced from the stalks, oil, or 7 cake, or the completely sterilized samples of seeds of the 8 plant which are incapable of germination is guilty of a 9 felony, which felony shall be known as "trafficking in 10 cannabis." Nothing in this subdivision shall apply to samples 11 of tetrahydrocannabinols including, but not limited to, all 12 synthetic or naturally produced samples of 13 tetrahydrocannabinols which contain more than 15 percent by 14 weight of tetrahydrocannabinols and which do not contain plant 15 material exhibiting the external morphological features of the 16 plant cannabis. If the quantity of cannabis involved: 17 "a. Is in excess of one kilo or 2.2 pounds, but less 18 than 100 pounds, the person shall be sentenced to a mandatory 19 minimum term of imprisonment of three calendar years and to 20 pay a fine of twenty-five thousand dollars ($25,000). 21 "b. Is 100 pounds or more, but less than 500 pounds, 22 the person shall be sentenced to a mandatory minimum term of 23 imprisonment of five calendar years and to pay a fine of fifty 24 thousand dollars ($50,000). Page 2 SB333 1 "c. Is 500 pounds or more, but less than 1,000 2 pounds, the person shall be sentenced to a mandatory minimum 3 term of imprisonment of 15 calendar years and to pay a fine of 4 two hundred thousand dollars ($200,000). 5 "d. Is 1,000 pounds or more, the person shall be 6 sentenced to a mandatory term of imprisonment of life without 7 parole. 8 "(2) Any person who knowingly sells, manufactures, 9 delivers, or brings into this state, or who is knowingly in 10 actual or constructive possession of, 28 grams or more of 11 cocaine or of any mixture containing cocaine, described in 12 Section 20-2-25(1), is guilty of a felony, which felony shall 13 be known as "trafficking in cocaine." If the quantity 14 involved: 15 "a. Is 28 grams or more, but less than 500 grams, 16 the person shall be sentenced to a mandatory minimum term of 17 imprisonment of three calendar years and to pay a fine of 18 fifty thousand dollars ($50,000). 19 "b. Is 500 grams or more, but less than one kilo, 20 the person shall be sentenced to a mandatory minimum term of 21 imprisonment of five calendar years and to pay a fine of one 22 hundred thousand dollars ($100,000). 23 "c. Is one kilo, but less than 10 kilos, then the 24 person shall be sentenced to a mandatory minimum term of Page 3 SB333 1 imprisonment of 15 calendar years and to pay a fine of two 2 hundred fifty thousand dollars ($250,000). 3 "d. Is 10 kilos or more, the person shall be 4 sentenced to a mandatory term of imprisonment of life without 5 parole. 6 "(3) Any person who knowingly sells, manufactures, 7 delivers, or brings into this state, or who is knowingly in 8 actual or constructive possession of, four grams or more of 9 any morphine, opium, or any salt, isomer, or salt of an isomer 10 thereof, including heroin, as described in Section 20-2-23(2) 11 or Section 20-2-25(1)a., or four grams or more of any mixture 12 containing any such substance, is guilty of a felony, which 13 felony shall be known as "trafficking in illegal drugs." If 14 the quantity involved: 15 "a. Is four grams or more, but less than 14 grams, 16 the person shall be sentenced to a mandatory minimum term of 17 imprisonment of three calendar years and to pay a fine of 18 fifty thousand dollars ($50,000). 19 "b. Is 14 grams or more, but less than 28 grams, the 20 person shall be sentenced to a mandatory minimum term of 21 imprisonment of 10 calendar years and to pay a fine of one 22 hundred thousand dollars ($100,000). 23 "c. Is 28 grams or more, but less than 56 grams, the 24 person shall be sentenced to a mandatory minimum term of Page 4 SB333 1 imprisonment of 25 calendar years and to pay a fine of five 2 hundred thousand dollars ($500,000). 3 "d. Is 56 grams or more, the person shall be 4 sentenced to a mandatory term of imprisonment of life without 5 parole. 6 "(4) Any person who knowingly sells, manufactures, 7 delivers, or brings into this state, or who is knowingly in 8 actual or constructive possession of 1,000 or more pills or 9 capsules of methaqualone, as described in Section 20-2-1, et 10 seq., is guilty of a felony, which felony shall be known as 11 "trafficking in illegal drugs." If the quantity involved: 12 "a. Is 1,000 pills or capsules, but less than 5,000 13 pills or capsules, the person shall be sentenced to a 14 mandatory minimum term of imprisonment of three calendar years 15 and pay a fine of fifty thousand dollars ($50,000). 16 "b. Is 5,000 capsules or more, but less than 25,000 17 capsules, that person shall be imprisoned to a mandatory 18 minimum term of imprisonment of 10 calendar years and pay a 19 fine of one hundred thousand dollars ($100,000). 20 "c. Is 25,000 pills or more, but less than 100,000 21 pills or capsules, the person shall be sentenced to a 22 mandatory minimum term of imprisonment of 25 calendar years 23 and pay a fine of five hundred thousand dollars ($500,000). Page 5 SB333 1 "d. Is 100,000 capsules or more, the person shall be 2 sentenced to a mandatory term of imprisonment of life without 3 parole. 4 "(5) Any person who knowingly sells, manufactures, 5 delivers or brings into this state, or who is knowingly in 6 actual or constructive possession of 500 or more pills or 7 capsules of hydromorphone as is described in Section 20-2-1, 8 et seq., is guilty of a felony which shall be known as 9 "trafficking in illegal drugs." If the quantity involved: 10 "a. Is 500 pills or capsules or more but less than 11 1,000 pills or capsules, the person shall be sentenced to a 12 mandatory term of imprisonment of three calendar years and to 13 pay a fine of fifty thousand dollars ($50,000). 14 "b. Is 1,000 pills or capsules or more, but less 15 than 4,000 pills or capsules, the person shall be sentenced to 16 a mandatory term of imprisonment of 10 calendar years and to 17 pay a fine of one hundred thousand dollars ($100,000). 18 "c. Is 4,000 pills or capsules or more but less than 19 10,000 pills or capsules, the person shall be sentenced to a 20 mandatory term of imprisonment of 25 calendar years and to pay 21 a fine of one hundred thousand dollars ($100,000). 22 "d. Is more than 10,000 pills or capsules, the 23 person shall be sentenced to a mandatory term of life in 24 prison without parole. Page 6 SB333 1 "(6) Any person who knowingly sells, manufactures, 2 delivers, or brings into this state, or who is knowingly in 3 actual or constructive possession of, 28 grams or more of 4 3,4-methylenedioxy amphetamine, or of any mixture containing 5 3,4-methylenedioxy amphetamine, is guilty of a felony, which 6 felony shall be known as "trafficking in illegal drugs." If 7 the quantity involved: 8 "a. Is 28 grams or more, but less than 500 grams, 9 the person shall be sentenced to a mandatory minimum term of 10 imprisonment of three calendar years and to pay a fine of 11 fifty thousand dollars ($50,000).
Load more

Recommended publications
  • Nové Rekreační Drogy
    Neurotoxikologie nových „legálních rekreačních drog“ ze skupin empatogenů/entaktogenů a disociativ MUDr. S. Zakharov, CSc. Toxikologické informa ční st ředisko1 Klinika pracovního léka řství Nové rekrea ční drogy („Legal Highs“) - pojem • Nové syntetické psychoaktivní látky neuvedené v Jednotné Úmluv ě o omamných látkách, v zákonu č. 167/1998 Sb.; • Prodávají se legáln ě přes internet („smartshops“, „rostliny- zahrada-online“, „výzkumné chemikálie“, e-inzeráty, aj.) • „Je to jako hra na chemickou ruskou ruletu, protože nejsou údaje o toxicit ě, biometabolitech, fakrmakokinetice…“ (John W. Huffman) • „Clubbers‘ drugs“ – používají ~40% návštěvníků no čních klub ů •Účinky: stimulanty, empatogeny/entaktogeny, halucinogeny (psychedelika, delirianty, disociativa), sedativa, a kombinace… 2 Nové rekrea ční drogy • Výroba v Jihovýchodní Asii, Číně, balení a distribuce v Evropě a Spojených Státech. • Jednoduchá schémata syntézy (2-3 chemické reakce, běžné reagens (toluen, aceton...), vysoká stupe ň chemické čistoty (99%), nízké ceny; • Chemická struktura je podobná struktuře zakázaných (kontrolovaných) psychoaktivních látek; • „Výzkumné chemikálie“ seznam.cz –– 51 odkaz; google.cz – 82 700 odkaz ů; • www.bulkresearchchemicals.com; http://vip- 3 legals.com; www.buyanychem.com MDMA („Extáze“, éčko, koláč) – 3,4- MetylenDioxy-N-Metyl Amfetamin) • Syntezována v r. 1912 (A.Kollisch, Merck), rekrea ční použití od r. 1963, zákaz - 1985 (SZO, USA). • „Droga lásky“: empatogen ( R. Metzner, 1983) nebo entaktogen ( D. Nichols, 1986) - indukce pocit ů empatie, vcítění, soudružnosti, lásky, emoční blízkosti. • MDMA-asistovaná psychoterapie v léčbě posttraumatických stresových poruch (PTSD), (výzkum sponzorován MAPS USA (Multidisciplinary Association For Psychedelic Studies). • V ČR „malé množství“ – do 4 tbl. (400 mg). 4 Mechanismus účinku a toxicita MDMA • Efektivně uvol ňuje a inhibuje zpětné vychytávání SER (afinita k presynaptic- kému SERT), méně – DAT, NAT • Mírně nespecificky inhibuje MAO (A, B) • Mírný agonista 5-HT2-Re (změna percepce), DA2- Re (euforia), NA-Re (symp-mim.
    [Show full text]
  • Endogenous Metabolites: JHU NIMH Center Page 1
    S. No. Amino Acids (AA) 24 L-Homocysteic acid 1 Glutaric acid 25 L-Kynurenine 2 Glycine 26 N-Acetyl-Aspartic acid 3 L-arginine 27 N-Acetyl-L-alanine 4 L-Aspartic acid 28 N-Acetyl-L-phenylalanine 5 L-Glutamine 29 N-Acetylneuraminic acid 6 L-Histidine 30 N-Methyl-L-lysine 7 L-Isoleucine 31 N-Methyl-L-proline 8 L-Leucine 32 NN-Dimethyl Arginine 9 L-Lysine 33 Norepinephrine 10 L-Methionine 34 Phenylacetyl-L-glutamine 11 L-Phenylalanine 35 Pyroglutamic acid 12 L-Proline 36 Sarcosine 13 L-Serine 37 Serotonin 14 L-Tryptophan 38 Stachydrine 15 L-Tyrosine 39 Taurine 40 Urea S. No. AA Metabolites and Conjugates 1 1-Methyl-L-histidine S. No. Carnitine conjugates 2 2-Methyl-N-(4-Methylphenyl)alanine 1 Acetyl-L-carnitine 3 3-Methylindole 2 Butyrylcarnitine 4 3-Methyl-L-histidine 3 Decanoyl-L-carnitine 5 4-Aminohippuric acid 4 Isovalerylcarnitine 6 5-Hydroxylysine 5 Lauroyl-L-carnitine 7 5-Hydroxymethyluracil 6 L-Glutarylcarnitine 8 Alpha-Aspartyl-lysine 7 Linoleoylcarnitine 9 Argininosuccinic acid 8 L-Propionylcarnitine 10 Betaine 9 Myristoyl-L-carnitine 11 Betonicine 10 Octanoylcarnitine 12 Carnitine 11 Oleoyl-L-carnitine 13 Creatine 12 Palmitoyl-L-carnitine 14 Creatinine 13 Stearoyl-L-carnitine 15 Dimethylglycine 16 Dopamine S. No. Krebs Cycle 17 Epinephrine 1 Aconitate 18 Hippuric acid 2 Citrate 19 Homo-L-arginine 3 Ketoglutarate 20 Hydroxykynurenine 4 Malate 21 Indolelactic acid 5 Oxalo acetate 22 L-Alloisoleucine 6 Succinate 23 L-Citrulline 24 L-Cysteine-glutathione disulfide Semi-quantitative analysis of endogenous metabolites: JHU NIMH Center Page 1 25 L-Glutathione, reduced Table 1: Semi-quantitative analysis of endogenous molecules and their derivatives by Liquid Chromatography- Mass Spectrometry (LC-TripleTOF “or” LC-QTRAP).
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 6,967,201 B1 Briner Et Al
    US006967201B1 (12) United States Patent (10) Patent N0.: US 6,967,201 B1 Briner et al. (45) Date of Patent: *Nov. 22, 2005 (54) BENZOFURYLPIPERAZINES AND (56) References Cited BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS U.S. PATENT DOCUMENTS 5,698,766 A 12/1997 Julius et 211. (75) Inventors: Karin Briner, Indianapolis, IN (US); 6,638,936 B1 * 10/2003 Briner et a1. Joseph Paul Burkhart, Plain?eld, IN (US); Timothy Paul Burkholder, FOREIGN PATENT DOCUMENTS Carmel, IN (US); Brian Eugene EP 0 006 524 A 1/1980 Cunningham, Martinsville, IN (US); EP 0 189 612 A 8/1986 Matthew Joseph Fisher, Mooresville, W0 W0 95 11243 A 4/1995 IN (US); William Harlan Gritton, W0 W0 97 08167 A 3/1997 Zionsville, IN (US); Shawn W0 W0 97 36893 A 10/1997 Christopher Miller, Noblesville, IN (US); J e?'rey Thomas Mullaney, OTHER PUBLICATIONS Indianapolis, IN (US); Matthew Robert Kuipers W. et al: “N4-unsubstituted 1-6 nl-arylpiperaZines Reinhard, Indianapolis, IN (US); as high-affinity 5 -HT1A recept r ligands” Journal of Medici Dennis Charles Thompson, nal Chemistry., vol. 38, No. 11, May 26, 1995, pp. 1942 Indianapolis, IN (US); Leonard Larry 1954, XP002153536 American Chemical Society. Washing Winneroski, Greenwood, IN (US); ton., US ISSN: 0022-2623. Yanping Xu, Fishers, IN (US) * cited by examiner (73) Assignee: Eli Lilly and Company, Indianapolis, Primary Examiner—Emily Bernhardt IN (US) (74) Attorney, Agent, or Firm—R. Craig Tucker (57) ABSTRACT (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
    [Show full text]
  • 124.204 Schedule I — Substances Included. 1. Schedule I Shall Consist
    1 , §124.204 124.204 Schedule I — substances included. 1. Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation: a. Acetylmethadol. b. Allylprodine. c. Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha- acetylmethadol, levomethadyl acetate, or LAAM). d. Alphameprodine. e. Alphamethadol. f. Alpha-Methylfentanyl (N-(1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl) propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine). g. Benzethidine. h. Betacetylmethadol. i. Betameprodine. j. Betamethadol. k. Betaprodine. l. Clonitazene. m. Dextromoramide. n. Difenoxin. o. Diampromide. p. Diethylthiambutene. q. Dimenoxadol. r. Dimepheptanol. s. Dimethylthiambutene. t. Dioxaphetyl butyrate. u. Dipipanone. v. Ethylmethylthiambutene. w. Etonitazene. x. Etoxeridine. y. Furethidine. z. Hydroxypethidine. aa. Ketobemidone. ab. Levomoramide. ac. Levophenacylmorphan. ad. Morpheridine. ae. Noracymethadol. af. Norlevorphanol. ag. Normethadone. ah. Norpipanone. ai. Phenadoxone. aj. Phenampromide. ak. Phenomorphan. al. Phenoperidine. am. Piritramide. an. Proheptazine. ao. Properidine. ap. Propiram. aq. Racemoramide. ar. Tilidine. as. Trimeperidine. at. Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-phenethyl)- 3-methyl-4-piperidinyl]-N-phenylpropanamide). Thu May 19 07:35:43 2016 Iowa Code 2016, Section 124.204 (25, 1) §124.204, 2 au. Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide). av.
    [Show full text]
  • Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives Strucrure-Acfivity RELA TIONSHIPS Ma
    Biochemieal PhannaeoloR)'. Vol. 54. pp. 1361-1369, 1997. ISSN 0006-2952/97/$17.00 + 0.00 © 1997 Elsevier Scienee Ine. Al! rights reserved. PIl SOOO6-2952(97)00405·X ELSEVIER Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives STRUcruRE-ACfIVITY RELA TIONSHIPS Ma. Cecilia Scorza,* Cecilia Carrau,* Rodolfo Silveira,* GemId Zapata,Torres,t Bruce K. Casselst and Miguel Reyes,Parada*t *DIVISIÓNBIOLOGíACELULAR,INSTITUTODEINVESTIGACIONESBIOLÓGICASCLEMENTeEsTABlE, CP 11600, MONTEVIOEO,URUGUAY;ANDtDEPARTAMENTODEQUíMICA, FACULTADDECIENCIAS,UNIVERSIDADDECHILE, SANTIAGO,CHILE ABSTRACT. The monoamine oxidase (MAO) inhibitory propenies of a series of amphetamine derivatives with difTerent substituents at or around rhe para position of the aromaric ring were evaluateJ. i¡, in viero stuJies in which a crude rar brain mirochllndrial suspension was used as rhe source of MAO, several compounds showed a srrong (ICS0 in rhe submicromolar range), selecrive, reversible, time-independenr, and concenrrarion-related inhibition of MAO-A. After i.p. injection, the compounds induced an inerease of serotonin and a decrease of j-hydroxyindoleacetic acid in the raphe nuclei and hippocampus, confinning rhe in virro results. The analysis of structure-activity relationships indicates rhat: molecules with amphetamine-Iike structure and different substitutions nn the aromaric ring are potentially MAO-A inhibitors; substituents at different positions of the aromatic ring moditY the porency but have litde inf1uence "n the selectiviry; substituents at rhe para position sllch as ,lmino, alkoxyl. halogens. or alkylthio produce a significant increase in rhe acrivity; the para-substituent musr be an e1ectron Jonor; hulky ~roups next to rhe para subsriruent Icad ro a Jecrease in the actÍ\'ityi ,ubstiruents loearcd ar posirions more Jistant ,m rhe aromaric ring havc less intluence anJ, even when the subsriruent is '1 halogen (CI, Br), an increase in rhe acrivity "f rhe cllmpound is llbtained.
    [Show full text]
  • Article 22 Regulation for Restriction of Synthetic Drugs
    ARTICLE 22 REGULATION FOR RESTRICTION OF SYNTHETIC DRUGS SECTION 22.1 AUTHORITY This regulation is promulgated under the authority granted to the Needham Board of Health under Massachusetts General Laws Chapter 111, Section 31 which states that “boards of health may make reasonable health regulations”. SECTION 22.2 PURPOSE The Needham Board of Health has found that synthetic marijuana, consisting of plant or other material treated with various chemicals or other synthetic substances not approved for human consumption, may be marketed and sold as herbal incense in the greater Boston area, although they are being used in the same manner and for the same purposes as scheduled drugs. In addition, the use of these products has become particularly popular among teens and young adults. Based on information and reports from hospitals, emergency room doctors, and police agencies, individuals who use these products experience dangerous side effects including convulsions, hallucinations, and dangerously elevated heart rates. This is evidence that synthetic marijuana products are harmful if inhaled or consumed, and present a significant public health danger. These synthetic compounds and others have a high potential for abuse and lack of any accepted medical use, these dangerous products, while not approved for human consumption, are marketed and sold in a form that allows for such consumption, putting at risk the individuals who come into contact with them. Therefore, the Needham Board of Health adopts this regulation for the purpose and with the intent to protect the public health and safety of the Town of Needham and its residents from the threat posed by the availability and use of synthetic marijuana, synthetic stimulants, synthetic hallucinogens, and other dangerous products by prohibiting persons from trafficking in, possessing, and using them within the town.
    [Show full text]
  • Copyrighted Material
    Index Note: page numbers in italics refer to figures; those in bold to tables or boxes. abacavir 686 tolerability 536–537 children and adolescents 461 acamprosate vascular dementia 549 haematological 798, 805–807 alcohol dependence 397, 397, 402–403 see also donepezil; galantamine; hepatic impairment 636 eating disorders 669 rivastigmine HIV infection 680 re‐starting after non‐adherence 795 acetylcysteine (N‐acetylcysteine) learning disability 700 ACE inhibitors see angiotensin‐converting autism spectrum disorders 505 medication adherence and 788, 790 enzyme inhibitors obsessive compulsive disorder 364 Naranjo probability scale 811, 812 acetaldehyde 753 refractory schizophrenia 163 older people 525 acetaminophen, in dementia 564, 571 acetyl‐L‐carnitine 159 psychiatric see psychiatric adverse effects acetylcholinesterase (AChE) 529 activated partial thromboplastin time 805 renal impairment 647 acetylcholinesterase (AChE) acute intoxication see intoxication, acute see also teratogenicity inhibitors 529–543, 530–531 acute kidney injury 647 affective disorders adverse effects 537–538, 539 acutely disturbed behaviour 54–64 caffeine consumption 762 Alzheimer’s disease 529–543, 544, 576 intoxication with street drugs 56, 450 non‐psychotropics causing 808, atrial fibrillation 720 rapid tranquillisation 54–59 809, 810 clinical guidelines 544, 551, 551 acute mania see mania, acute stupor 107, 108, 109 combination therapy 536 addictions 385–457 see also bipolar disorder; depression; delirium 675 S‐adenosyl‐l‐methionine 275 mania dosing 535 ADHD
    [Show full text]
  • MDAI (5,6Methylenedioxy2aminoindane
    human psychopharmacology Hum. Psychopharmacol Clin Exp 2013; 28: 345–355. Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/hup.2298 SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H- cyclopenta[f][1,3]benzodioxol-6-amine; ‘sparkle’; ‘mindy’) toxicity: a brief overview and update John M Corkery1,3*, Simon Elliott2, Fabrizio Schifano1,3, Ornella Corazza3 and A Hamid Ghodse1,† 1National Programme for Substance Abuse Deaths (np-SAD), International Centre for Drug Policy, St George’s, University of London, London, UK 2ROAR Forensics Ltd, Malvern, Worcestershire, UK 3School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire, UK Objectives MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; ‘sparkle’; ‘mindy’)isa psychoactive substance, sold primarily over the Internet and in ‘head’ shops as a ‘legal high’. Synthesised and used as a research chemical in the 1990s, MDAI has structural similarities to MDMA (3,4-methylenedioxy-N-methylamphetamine) and shares its behavioural properties. Recreational use of MDAI appears to have started in Europe around 2007, with a noticeable increase after 2009 in the UK and other countries. Calls to National Poisons Information Services started in 2010, although there were few presentations to emergency departments by patients complaining of undesirable physical and psychiatric effects after taking MDAI. Recreational use of this drug has been reported only occa- sionally by online user fora. There is little scientifically based literature on the pharmacological, physiological, psychopharmacological, tox- icological and epidemiological characteristics of this drug. Methods Recent literature (including ‘grey’) was searched to update what is known about MDAI, especially on its toxicity.
    [Show full text]
  • BOARD MEETING AGENDA Meeting Location: Portland State Office Building 800 NE Oregon Street, Portland, OR 97232 June 6-7, 2018 Updated 6.4.18
    Oregon Board of Pharmacy BOARD MEETING AGENDA Meeting Location: Portland State Office Building 800 NE Oregon Street, Portland, OR 97232 June 6-7, 2018 Updated 6.4.18 The mission of the Oregon State Board of Pharmacy is to promote, preserve and protect the public health, safety and welfare by ensuring high standards in the practice of pharmacy and by regulating the quality, manufacture, sale and distribution of drugs. Wednesday, June 6, 2018 @ 8:30AM – Conference Rm A Thursday, June 7, 2018 @ 8:30AM – Conference Room A ≈ If special accommodations are needed for you to attend or participate in this Board Meeting, please contact Loretta Glenn at: (971) 673-0001. ≈ WEDNESDAY, JUNE 6, 2018 I. 8:30AM OPEN SESSION, Penny Reher, R.Ph, Presiding A. Roll Call B. Agenda Review and Approval Action Necessary II. Contested Case Deliberation pursuant to ORS 192.690(1) - Not Open to the Public III. EXECUTIVE SESSION – NOT OPEN TO THE PUBLIC, pursuant to ORS 676.175, ORS 192.660 (1) (2) (f) (k). A. Items for Consideration and Discussion: 1. Deliberation on Disciplinary Cases and Investigations 2. Personal Appearances 3. Deficiency Notifications 4. Case Review B. Employee Performance Review pursuant to ORS 192.660(2)(i). IV. OPEN SESSION - PUBLIC MAY ATTEND - At the conclusion of Executive Session, the Board may convene Open Session to begin some of the following scheduled agenda items - time permitting at approximately 3:30PM. V. Approve Consent Agenda* Action Necessary *Items listed under the consent agenda are considered to be routine agency matters and will be approved by a single motion of the Board without separate discussion.
    [Show full text]
  • General Drug and Explosive Detection
    Ζ'HQWDȇV'UXJ'HWHFWLRQDQGΖGHQWLILFDWLRQWHVWNLWVRIIHUEUHDNWKURXJKLQQRYDWLRQVORQJ DZDLWHGE\WKHIRUHQVLFPDUNHW8QWLOUHFHQWO\RQO\GLIILFXOWWRXVHDQGKDUGWRXQGHUVWDQG WHVWNLWVZLWKPDQ\FRQVWUDLQWVDQGOLPLWDWLRQVZHUHDYDLODEOHΖ'HQWDȇVNLWVPDNHWKH WDVNVIDFHGE\SDUHQWVHGXFDWRUVHPSOR\HUVDQGODZHQIRUFHPHQWRIILFHUVHDVLHU IDVWHUIDUVDIHUDQGPRUHFRVWHIIHFWLYHWKDQDQ\VLPLODUNLWDYDLODEOH .H\%HQHILWV .H\0DUNHWV ႑(DV\IDVWDQGVLPSOHWRXVH1RRWKHUWHVWVDUH ႑/DZHQIRUFHPHQW DVVWUDLJKWIRUZDUG ႑0LOLWDU\ ႑$FFXUDWHDQGUHOLDEOHDWH[WUHPHWHPSHUDWXUHV ႑&XVWRPV ႑&OHDUUHVXOWVLQVHFRQGV ႑6HFXULW\DJHQFLHV ႑/RQJVKHOIOLIH XSWR\HDUV ZLWKQRVWRUDJH ႑*RYHUQPHQWDJHQFLHV UHVWULFWLRQV ,'7 '($)%Ζ&Ζ$ ,'7 ,'7 ႑6DIH$FWXDOO\YHU\VDIH1RFRQWDFWZLWK *HQHUDO6FUHHQLQJ ႑3ULVRQV FKHPLFDOVRUVXEVWDQFHV1RLQKDODWLRQRI .HWDPLQH /LTXLG *+% 'UXJV &RUSRUDWH+5GHSDUWPHQWV YDSRUVQRSURWHFWLYHJHDUQHHGHG ႑ ΖGHQWLILFDWLRQ ΖGHQWLILFDWLRQ ΖGHQWLILFDWLRQ ႑6DIHWRGLVSRVH6HOIFRQWDLQHGQHXWUDOL]DWLRQ ႑3ULYDWHUHVLGHQFHV )LHOG7HVW.LW ႑6PDOODQGYHU\UXJJHG ႑6FKRROV8QLYHUVLWLHV )LHOG7HVW.LW )LHOG7HVW.LW ႑&DQEHXVHGDQ\ZKHUHDQ\WLPH ႑5HKDELOLWDWLRQIDFLOLWLHV ႑7KHFRORUWHVWLVEDVHGRQWKHVDPHFKHPLVWU\DV ႑ƀ+\GUR[\EXW\ULFDFLG *+% LVDFHQWUDO ႑7KHWHVWGHWHFWVGUXJVLQFOXGLQJFRFDLQH ႑$YDLODEOHZLWKYDULRXVSUREHV ႑%RUGHUFRQWURO IRUWKHVROLGWHVW QHUYRXVV\VWHPGHSUHVVDQWXVHGDVDQ KHURLQDPSKHWDPLQHHFVWDV\DVZHOODVQHZ 7RXFK6ZLSH6QLIIHURU6DPSOHU LQWR[LFDQW GHVLJQHUGUXJV ႑(PHUJHQF\URRPV ႑7KHNLWFRQWDLQVDQRYHOVDPSOHUIRUWKHHDV\ ႑2XUNLWV'2WHVWOLTXLGV WHVWLQJRIOLTXLGV ႑&RPPRQVWUHHWQDPHVLQFOXGH*/LTXLG ႑7KHWHVWLVEDVHGRQDQRYHOFRORUWHVWIRU */LTXLG;/LTXLG(*HRUJLD+RPH%R\ DONDORLGV
    [Show full text]
  • Aminoindanesthe Next Wave of Legal Highs?
    Drug Testing Review and Analysis Received: 23 May 2011 Accepted: 24 May 2011 Published online in Wiley Online Library: 11 July 2011 (www.drugtestinganalysis.com) DOI 10.1002/dta.318 Aminoindanes – the next wave of ‘legal highs’? P.D. Sainsbury,a A.T. Kicman,a R.P. Archer,b L.A. Kinga and R.A. Braithwaitea∗ Due to its closed ring system, 2-aminoindane is a conformationally rigid analogue of amphetamine. Internet websites offering synthetic compounds as ‘research chemicals’ have recently been advertising 5,6-methylenedioxy-2-aminoindane (MDAI), 5, 6-methylenedioxy-N-methyl-2-aminoindane (MDMAI), 5-iodo-2-aminoindane (5-IAI), and 5-methoxy-6-methyl-2-aminoindane (MMAI). The chemistry, pharmacology, and toxicological aspects of this new class of psychoactive substances are reviewed, as these could become the next wave of ‘legal highs’. Copyright c 2011 John Wiley & Sons, Ltd. Keywords: aminoindanes; legal highs; MDAI; MDMAI; 5-IAI; MMAI; serotonin. Introduction Pharmacology Although Solomons and Sam reported in 1973 that the aminoin- Historically, the terms ‘legal highs’ and ‘herbal highs’ referred to danes possessed significant bronchodilating and analgesic blends of psychoactive plants or fungi that could be smoked properties,[2] more recent research points to the aminoindanes as or ingested to induce dissociative effects and hallucinations. having potent effects on serotonin release and re-uptake. A num- These terms, however, have more recently been widened to ber of studies undertaken in the late 1980s and early 1990s con- describe an extensive and growing range of entirely synthetic cerning Ecstasy (3,4-methylenedioxymethamphetamine; MDMA) substances that have become popular as recreational drugs of also included a comparison with a number of MDMA analogues abuse; this coincides with a period of intense media interest that incorporated an indane ring.
    [Show full text]